[Translation] A multicenter, open-label, non-randomized phase I/II clinical trial to evaluate the safety, tolerability, radiation dosimetry and anti-tumor activity of lutetium[177Lu]JH020002 injection in patients with advanced prostate cancer
评价镥[177Lu]JH020002注射液治疗转移性前列腺癌的安全性和耐受性,并探索镥[177Lu]JH020002注射液的最大耐受剂量(MTD),为后续研究提供推荐剂量(RP2D)(I期);评价镥[177Lu]JH020002注射液治疗转移性前列腺癌的抗肿瘤活性(II期)。
[Translation] To evaluate the safety and tolerability of Lutetium[177Lu]JH020002 injection in the treatment of metastatic prostate cancer, and to explore the maximum tolerated dose (MTD) of Lutetium[177Lu]JH020002 injection to provide a recommended dose (RP2D) for subsequent studies (I Phase); to evaluate the anti-tumor activity of lutetium [177Lu] JH020002 injection in the treatment of metastatic prostate cancer (Phase II).